In ChromaDex, Inc. v. Elysium Health, Inc., No. 22-1116 (Fed. Cir. Feb. 13, 2023), the Court of Appeals for the Federal Circuit (“the Federal Circuit”) affirmed the district court’s grant of summary judgment that the claims at issue, directed to dietary supplements, were unpatentable as ineligible subject matter under 35 U.S.C. § 101.
